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Partnerships are sine qua nons for effective work in
international health. While individuals, institutes, and
agencies comprise the usual coalitions, linkages between
research, training, and control activities are also essential in
international science and public health, and a balance
between these components must be fostered. Support for
research is particularly important when effective disease
control interventions do not exist or are not available for
managing emerging or reemerging infectious diseases. The
five presentations in this panel represent outstanding
examples of the need for close links between research,
training, and control activities.
In 1998, the Burroughs Wellcome Fund (BWF) and the
Wellcome Trust launched a joint research effort focused on
infectious diseases of the tropical developing world. This
grant program addresses parasitic, bacterial, fungal, and
non-HIV/AIDS related viral infections of importance to
developing tropical countries and their collaborators in
developed nations. The North American and United Kingdom
institutions that have funded projects must make the tropics
their center of operations. The program is an experiment for
the fund, allowing the BWF to explore a new, collaborative
approach to health philanthropy compared to prior experience
when focus was on a specific scientific topic, often
investigated outside of tropical areas. (See Victoria
McGovern’s article in this issue on p. 564.)
The Fogarty International Center (FIC) of the National
Institutes of Health (NIH) advances health research through
international scientific cooperation and is the center for NIH
international activities. The Multilateral Initiative on
Malaria (MIM) is an alliance of organizations and individuals
that aim to facilitate international collaboration and
cooperation in scientific research that will lead to the control
of malaria. The rotating secretariat of MIM was moved from
the Wellcome Trust to the FIC in 1999 on recommendation of
the partners. To ensure that research findings are applied to
malaria treatment and control, scientists in malaria-endemic
countries must be at the forefront of research addressing the
local malaria situation.
MIM supports research that will lead to better use of
current control methods and development of new and
sustainable methods of malaria control in endemic countries.
MIM works to strengthen and sustain malaria research
capacity in endemic countries through regional and
international scientific collaboration and training. It
promotes regional and international communication and
cooperation to maximize the impact of resources and to avoid
the duplication of effort. MIM also aims to facilitate dialogue
between researchers and control program personal in
malaria-endemic countries to promote research that will
address the needs of malaria control programs and eventually
encourage collaborative research between these two groups.
Finally, MIM facilitates communication among scientists,
public health professionals, and policymakers to ensure that
research findings lead to policy changes at the government
and international levels.
The research grant component of MIM remains with the
Special Programme for Research and Training in Tropical
Diseases (TDR)/World Health Organization program. The
task force on malaria Research Capability Strengthening
(RCS) in Africa, coordinated by the United Nations
Development Programme/World Bank and WHO Special
Programme for Research and Training in Tropical Diseases
(TDR), represents a collaborative funding strategy involving
multiple agencies and governments to promote capacity-
building activities carried out by MIM in Africa. (See Fabio
Zicker’s article in this issue on  p. 529.)
Members of the East African AIDS Training Initiative
have developed a model for HIV/AIDS education and training
for community-based health- care workers at the grass roots
level. The goal was to implement a community-owned
program which could be readily adapted for the needs of any
resource-poor community. Two factors led to developing the
program. First, requests were received for education and
training from members of the health-care community in
Nairobi; second, education and training delivered at the grass
roots level is believed to be the most effective vehicle for
introducing rapid social change. This program involved a 3-
day residential workshop and continues to be monitored with
quarterly site visits in support of participants. Outcomes
demonstrate the positive effects of partnerships among
community members, funding organizations, and individual
charitable donors. The careful development of individual
action plans coupled with ongoing support of training mentors
via site visits has contributed to the success of this program.
The International Trachoma Initiative is focusing on the
world’s leading cause of preventable blindness. An estimated
6 million people are blind or visually impaired due to
trachoma, and an additional 150 million have the disease.
Trachoma is an infectious disease caused by the bacterium
Chlamydia trachomatis. The disease is most common in
children but causes blindness in adults, particularly women.
Poverty is the fundamental determinant of trachoma. It
results in a lack of basic sanitation, medical care, drugs, and
education on prevention and cure in trachoma-endemic areas.
Pfizer, Inc. and the Edna McConnell Clark Foundation
founded the International Trachoma Initiative (ITI) in
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November 1998 with the explicit mission of working to
advance the elimination of trachoma and the blindness it
causes. A WHO-approved strategy called SAFE is simple,
sustainable, and addresses both cure and prevention:
Surgery for trichiasis—the immediate precursor to
blindness
Antibiotics to treat active disease
Facial cleanliness to reduce transmission
Environmental improvement to control the agents of the
disease
In ITI countries the antibiotic used is Zithromax
(azithromycin), donated by Pfizer. A single oral dose of
Zithromax once a year is as effective as the standard
treatment of tetracycline eye ointment 2 times a day for 6
weeks. The ITI is currently working in five countries:
Morocco, Tanzania, Mali, Ghana, and Vietnam. The ITI works
with ministries of health to devise an operating plan and joins
WHO, United Nations Children’s Fund, and nongovernmen-
tal organizations to carry out this work.
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In the 1960s, the United States began to lose interest in
public health.  The development of effective vaccines and
antibiotics, combined with the long-term benefits of
sanitary reforms begun 100 years earlier, fostered the
belief that communicable diseases had been conquered and
that it was time to focus the nation’s resources on chronic
diseases such as cancer and heart disease.  This shift led to
the deterioration of the public health infrastructure,
including public health law training and practice.  At the
same time, bioethics and the legal specialty of health law
began to evolve.  Both of these fields were individual-
centered: bioethics concentrated in individual autonomy and
health law concentrated on the delivery of, and reimburse-
ment for, personal health services.  By the 1980s, legal
discourse and training on health and public health was
dominated by an individual-centered jurisprudence that
subordinated the public’s interest to that of the individual.
Although this approach resulted in important advances in
patient autonomy, it undermined the public’s understand-
ing and acceptance of the traditional role of public health
law—the protection of the health of the population.  Many
states weakened their communicable disease-reporting
laws and otherwise made it more difficult to identify and
manage communicable disease threats.  More critically,
public health professionals began to believe that they do
not have the legal authority to restrict individual behavior
to protect the public health and that their role is to provide
personal health services on the same basis as private
health care providers.
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The threat of emerging infectious diseases and
bioterrorism is forcing the states and the federal government
to reassess the U.S. public health infrastructure and the
provision of public health services, as well as to review
international treaties and trade agreements to ensure that
they are consistent with effective public health measures.  As
part of this process, it is critical to ensure that each
jurisdiction has adequate legal authority to protect the health
of the public and to act quickly in the face of bioterrorism or a
disease outbreak.  This will require the restoration of more
traditional public health laws in some jurisdictions and the
training of lawyers, judges, and public health professionals in
public health jurisprudence.  The federal government should
help coordinate state efforts and should ensure that there are
no federal law impediments to effective public health
enforcement.
The restoration and expansion of the public health
infrastructure and the development of more effective public
health legal services will have many benefits beyond
improving the response to emerging infectious diseases and
bioterrorism.  Achieving these goals is also essential to the
improvement of the delivery of routine public health services
such as food sanitation, immunizations, and the abatement of
hazardous environmental conditions.
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at the University of Missouri-Kansas City School of Law.  His research in-
terests focus on public health and biotechnology. For more information on
public health law and practice, contact the Center for Public Health Law
through its Web site: http://plague.law.umkc.edu/cphl.